To hear about similar clinical trials, please enter your email below
Trial Title:
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
NCT ID:
NCT01374659
Condition:
Thyroid Cancer
Recurrence
Conditions: Official terms:
Carcinoma
Thyroid Neoplasms
Thyroid Diseases
Recurrence
Conditions: Keywords:
124-I PET
FDG-PET
PET/CT
recurrence
differentiated thyroid carcinoma
diagnostic value
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Summary:
Several studies have indicated that [124I]-PET/CT or [18F]-FDG-PET/CT may be useful to
locate recurrent differentiated thyroid carcinoma lesions in patients with elevated
thyroglobulin levels but who do not show pathological lesions when conventional imaging
modalities are used. Thus, the investigators evaluated the effectiveness of PET/CT using
both [124I] and [18F]-FDG in such patients.
Detailed description:
Patients with histologically proven DTC were studied. All patients
had previously undergone total thyroidectomy and more than one session of postoperative
RI therapy. More than 12 months of follow-up after the last RI therapy session, all
patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation
(TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in
any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients
with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were
excluded from the study. The work was approved by our Institutional Review Board and
written informed consent was obtained from each patient.
The study was prospectively designed to evaluate the diagnostic
efficacies of [18F]-FDG-PET/CT and [124I]-PET/CT in patients with elevated Tg levels, but
who yielded no pathological findings on conventional imaging. The [124I] radioisotope was
supplied by the Radiopharmaceutical Research Team of the Korea Institute of Radiological
and Medical Sciences (KIRAMS). All involved patients underwent a diagnostic [131I] scan,
[18F]-FDG-PET/CT, and [124I]-PET/CT. On the first day (D1) of the study, blood and urine
were collected for routine examination; to measure blood TSH, Tg, and anti-Tg antibody
levels; and to assess urine iodine excretion after 4 weeks of levothyroxine (LT4)
withdrawal. All patients had consumed a low-iodine diet for the prior 2 weeks, following
written instructions and assisted by a dietician. On the second day (D2) of the study, an
[131I] scan was obtained 48 h after administration of 74 MBq of [131I]. On day 10 (D10)
of the study, patients fasted for at least 4 h before examination, and were
(intravenously) given 370 MBq [18F]-FDG. All patients were instructed to rest comfortably
for 60 min and to empty the bladder before scanning. Whole-body PET/CT images were
obtained using a Discovery ST scanner (GE Healthcare, Milwaukee, WI). Seven or eight
frames (3 min/frame) of emission PET data were acquired in the two-dimensional mode after
noncontrast CT scans had been performed from the base of the skull to the upper thigh
(tube rotation time of 1 s per revolution; 120 kV; 60 mA; 7.5 mm per rotation; and an
acquisition time of 60.9 s for a scan length of 867 mm). Emission PET images were
reconstructed via non-contrast CT using an iterative method (ordered-subsets expectation
maximization with two iterations and 30 subsets; field of view 600 mm; slice thickness
3.27 mm). Attenuation-corrected PET/CT images were reviewed on an Xeleris workstation (GE
Healthcare). All images were independently interpreted by two experienced nuclear
medicine physicians and screened for "hot spots" indicative of hypermetabolic
abnormalities.
On day 11 (D11) of the study, 24 h after administration of an [124I] trace dose (74 MBq),
whole-body PET/CT scans were obtained using the Discovery ST scanner. First, a
non-enhanced CT scan was performed, from the base of the skull to the upper thigh (tube
rotation time of 1 s per revolution; 140 kV; 80 mA; 3.75 mm per rotation; acquisition
time of 23.9 s for a scan length of 804 mm). Subsequently, seven or eight frames (5 min
per frame) of emission PET data were acquired in the two-dimensional mode and
reconstructed via CT using an iterative method (software from General Electric Medical
Systems; ordered-subsets expectation maximization with two iterations and 21 subsets;
field of view 600 mm; slice thickness 3.27 mm).
To ensure that the interpretation of [18F]-FDG-PET/CT and [124I]-PET/CT
data was performed under similar conditions, all physicians who initially read images of
one type were deliberately blinded to the results of the other type of imaging, and to
patient clinical data. This was achieved by ensuring that the interpreting physicians
were not involved in patient clinical care. Findings on [18F]-FDG-PET and [124I]-PET
scanning were compared with data from diagnostic and post-therapeutic [131I] scans.
Moreover, the data were compared with those of radiological imaging (US, CT, and MRI
information), and/or those of cytological investigation (FNAC), to confirm (or otherwise)
the findings of the [131I] scans, and those of both forms of PET/CT (using [18F]-FDG and
[124I]). For each patient, the presence or absence, and number and localization of any
recurrent lesions (if present) were determined. The data of both types of PET/CT scans
were classified as follows: 1) True-positive, if pathologic [18F]-FDG or [124I] uptake
was proven by histology, cytology, or other imaging techniques, and caused therapy to be
changed; 2) False-positive, if no pathologic [18F]-FDG or [124I] uptake was seen (such
observations were of no clinical consequence); 3) True-negative, if no [18F]-FDG or
[124I] uptake was found and the patient had neither an elevated Tg level nor any evidence
of recurrence upon subsequent follow-up; and, 4) False-negative if no [18F]-FDG or [124I]
uptake was noted despite elevated Tg levels, even if positive findings were obtained when
other imaging methods were employed.
Criteria for eligibility:
Study pop:
Study patients who underwent total thyroidectomy with more than one of high dose
radioactive iodine treatment, showed elevated Tg levels, but who yielded no pathological
findings on conventional imaging during follow-up period.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Study patients with histologically proven DTC were studied. All patients had
previously undergone total thyroidectomy and more than one session of postoperative
RI therapy.During follow-up after the last RI therapy session, all patients showed
increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30
mU/l). However, neither tumor recurrence nor metastasis could be detected in any
patient by post-therapeutic [131I] scanning, neck US, or chest radiography.
Exclusion Criteria:
- Patients with obvious cervical pathology or positive fine-needle aspiration cytology
(FNAC) were excluded from the study. The work was approved by our Institutional
Review Board and written informed consent was obtained from each patient.
Gender:
All
Minimum age:
15 Years
Maximum age:
85 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Jandee Lee
Address:
City:
Suwon
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Jandee Lee, MD
Phone:
82-31219-5200
Email:
jandee@ajou.ac.kr
Start date:
July 2009
Completion date:
August 2012
Lead sponsor:
Agency:
Korean Association of Endocrine Surgeons
Agency class:
Other
Source:
Korean Association of Endocrine Surgeons
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01374659